Baker Bros. Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options

As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix BakersBaker Bros Advisors, a fund focused on the biotechnology and healthcare companies, have revealed upping its long stake in Synageva BioPharma Corp (NASDAQ:GEVA). According to the filing, Baker Bros. have purchased close to 29,800 shares of the company at a price of $60.45 apiece. The price, which is much lower in comparison with the current stock price of Synageva BioPharma, was obtained following the conversion of the Non-Qualified Stock Options, held by the fund since 2005. In this way, currently, Baker Bros. owns almost 10.88 million shares of the company.

Synageva BioPharma

Earlier in April, Baker Bros has also converted options to purchase 56,000 shares of Synageva BioPharma Corp (NASDAQ:GEVA) at a price of $65.10 per share, held since 2007. In this way, Baker Bros. has solidified its position as one of the largest shareholders of the company.

The stock of Synageva BioPharma Corp (NASDAQ:GEVA) has surged by around 62% since the beginning of the year, and by 150% over the past year. The company has posted a significant net loss for the first quarter of the year, of $36.4 million, versus $14.5 million for the same period of the last year, while its revenue amounted to $1.6 million. According to a statement Synageva BioPharma Corp (NASDAQ:GEVA) is working on the development of its ARISE drug for Lysosomal Acid Lipase Deficiency treatment and plans to report top-line results from the Phase 3 trial during the third quarter of the year.

Other investors, among the funds we track, hold smaller positions in Synageva BioPharma. Jerome Pfund and Michael Sjostrom‘s Sectoral Asset Management owns 465,145 shares as of the end of March, down by 37% of the quarter. On the other hand, James E. Flynn‘s Deerfield Management and Donald Chiboucis‘ Columbus Circle Investors have initiated stakes in the company during the first quarter, reporting ownership of 317,700 shares and 186,300 shares of Synageva BioPharma Corp (NASDAQ:GEVA) respectively in their latest 13F filings.

Disclosure: none

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!